Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Thermo Fisher Scientific acquires Propel Labs and its cell sorting tech

By Sean Whooley | February 17, 2021

Thermo Fisher Scientific (NYSE:TMO) announced today that it acquired cell sorting technology assets from SIDIS Corp. subsidiary Propel Labs.

Waltham, Mass.-based Thermo Fisher’s agreement with Propel Labs stipulates that the recently introduced Bigfoot spectral cell sorter and approximately 40 employees will become part of Thermo Fisher’s biosciences business unit, while Propel Labs will continue to operate as a separate entity with its remaining assets, according to a news release.

The Bigfoot spectral cell sorter is designed to accelerate soring up to 10 times faster than other available technologies can while maintaining cell viability and offering improved ease of use. Additionally, the technology has an integrated Class II biocontainment system to eliminate the need for separate biosafety cabinets.

Thermo Fisher said that the new technology offers more opportunities to study more cell populations from samples of limited quantity to enable a better understanding of biological systems.

“Cell sorting is an essential discovery tool used by many of our customers, allowing for the separation of specific cell types from complex samples. A first-of-its kind, the Bigfoot spectral cell sorter brings more powerful sorting capabilities, faster throughput and novel safety features complementing our already strong flow cytometry offering,” Thermo Fisher EVP & COO Mark Stevenson said in the release. “As the market for cell and gene therapies, immuno-oncology and other promising medicines drive increased expectations from researchers, we are really well-positioned to support our customers in their work to improve healthcare outcomes.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

Ivermectin not supported for mild COVID-19, study says
Emulate Bio
Organ-chips could streamline drug development, but hurdles remain
Novavax
Novavax stock dips 14% on the heels of Q4 announcement
Amgen/AstraZeneca
After flunking one study, Amgen’s tezepelumab shows promise for asthma

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards